Baseline EDSS, length of follow-up and disability outcomes based on the area under the curve of the EDSS versus follow-up time plot of n=87 alemtuzumab-treated patients.
| Alemtuzumab-treated patients (n=87) | |
|---|---|
| Mean duration of follow-up (months) to last clinic review | 86.1 (±23.9) |
| Mean duration of follow-up (months±SD) to last EDSS | 77.0 (±25.5) |
| Median baseline EDSS (IQR) | 3.5 (2.0–6.0) |
| Median last recorded EDSS (IQR) | 3.5 (2.0–5.5) |
| 6-month confirmed sustained reduction in disability | 30/69 (43.5%) |
| 6-month confirmed sustained accumulation of disability | 28/87 (32.2%) |
| Median area under the curve (AUC) value (IQR) | −0.46 (−6.97–2.90) |
| Patients with a ‘net improved’ AUC value (AUC value <−0.5) | n=43 (49.4%) |
| Patients with a ‘net unchanged’ AUC value (AUC value ≥−0.5, ≤0.5) | n=9 (10.4%) |
| Patients with a ‘net worse’ AUC value (AUC value >0.5) | n=35 (40.2%) |
EDSS, Expanded Disability Status Scale.